Audited Financial Result for quarter and year ended 31 March, 2026.
JHS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty Microcap 250 and 2.5 pts more than its Personal Care peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
JHS Svendgaard Laboratories reported FY26 revenue of Rs 10,169.47 lakhs, up 10.5% from Rs 9,199.73 lakhs in FY25. The company reduced its net loss significantly to Rs 191.73 lakhs from Rs 1,973.84 lakhs in FY25, showing operational improvement. Q4 FY26 saw revenue of Rs 3,269.57 lakhs but a net loss of Rs 356.56 lakhs. The auditors issued an unmodified opinion but drew attention to Rs 4,190.82 lakhs in capital advances for manufacturing facilities in Himachal Pradesh and a Jammu & Kashmir project, which management considers recoverable. The company provided a Rs 500 lakh corporate guarantee to its subsidiary JHS Svendgaard Retail Venture Limited. Auditors also flagged weaknesses in internal controls over trade receivables/payables reconciliation, inventory monitoring, and TDS tracking.
The company is still loss-making but has substantially narrowed losses compared to the previous year. The large capital advances and internal control weaknesses may concern investors, though the clean audit opinion and improving revenue trajectory are positives.